Template:ヒトの体温

脚注

  1. ^ Marx, John (2006). Rosen's emergency medicine: concepts and clinical practice. Mosby/Elsevier. p. 2239. ISBN 978-0-323-02845-5
  2. ^ Karakitsos D, Karabinis A (September 2008). "Hypothermia therapy after traumatic brain injury in children". N. Engl. J. Med. 359 (11): 1179–80. doi:10.1056/NEJMc081418. PMID 18788094
  3. ^ a b Axelrod YK, Diringer MN (May 2008). "Temperature management in acute neurologic disorders". Neurol. Clin. 26 (2): 585–603, xi. doi:10.1016/j.ncl.2008.02.005. PMID 18514828
  4. ^ a b Laupland KB (July 2009). “Fever in the critically ill medical patient”. Crit. Care Med. 37 (7 Suppl): S273–8. doi:10.1097/CCM.0b013e3181aa6117. PMID 19535958. 
  5. ^ Grunau BE, Wiens MO, Brubacher JR (September 2010). "Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review". CJEM. 12 (5): 435–442. PMID 20880437. Dantrolene may also be associated with improved survival and reduced complications, especially in patients with extreme (≥ 42°C) or severe (≥ 40°C) hyperpyrexia
  6. ^ Sharma HS, ed. (2007). Neurobiology of Hyperthermia (1st ed.). Elsevier. pp. 175–177, 485. ISBN 9780080549996. 2016年11月19日閲覧Despite the myriad of complications associated with heat illness, an elevation of core temperature above 41.0°C (often referred to as fever or hyperpyrexia) is the most widely recognized symptom of this syndrome.